New technologies for human cancer imaging.

By John V. Frangioni. Journal of Clinical Oncology, 2008

712 citations recorded by the source corpus.

Subfields: Biomedical Engineering, Radiology, Nuclear Medicine and Imaging

View Paper: https://www.semanticscholar.org/paper/4df74cce656ff017e42e45d837548ffb3796bf5f

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Biomedical Engineering

1. Hak Soo Choi
2. Joost R. van der Vorst
3. M. Hutteman
4. John V. Frangioni

In Radiology, Nuclear Medicine and Imaging

1. Hak Soo Choi
2. Valery V. Tuchin
3. John V. Frangioni
4. E. Genina
5. A. Bashkatov

Citations in the corpus

• The clinical use of indocyanine green as a near-infrared fluorescent contrast agent for image-guided oncologic surgery (2011, background): “Advantages of NIR fluorescent light (700–900 nm) include high tissue penetration (millimetres to centimetres deep) and low autofluorescence, thereby providing sufficient contrast [1].”
• The FLARE™ Intraoperative Near-Infrared Fluorescence Imaging System: A First-in-Human Clinical Trial in Breast Cancer Sentinel Lymph Node Mapping (2009, background): “is amenable to targeted contrast agents, which are a requirement for many procedures, such as image-guidance oncologic surgery (reviewed by Frangioni).(1)”
• A Review of Indocyanine Green Fluorescent Imaging in Surgery (2012, background): “Some of the proposed new molecules are based on ICG, while there are also totally different approaches such as quantum dot-based contrast agents [31, 32].”
• Early detection of cancer (2022, neutral): “M olecular imaging technologies, such as MRI ( 95 ) and PET ( 96 ), can perform early diagnosis and staging.”
• Photoacoustic imaging in cancer detection, diagnosis, and treatment guidance (2011, neutral): “1–100 μm) than USI (50–500 μm), MRI (10–100μm), CT (50–200 μm), PET (1–2 mm) and SPECT (1–2 mm), and can detect a lower number of cancer cells per imaging voxel [3].”
• Nanoparticles for Biomedical Imaging: Fundamentals of Clinical Translation (2010, background): “The term ‘‘effect size’’ refers to the ‘‘signal strength’’ of a diagnostic, therapeutic, or theragnostic agent.(5,16) Unlike small molecules, which often have limited effect size, NPs can produce high signal to background ratios (SBRs), can provide simultaneous contrast for multiple imaging modaliti”